We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

880:HKEXSJM Holdings Limited Analysis

Data as of 2026-03-17 - not real-time

¥3,841.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Tokyo Tatemono trades at a trailing PE of 13.6×, well below the industry average of 33×, and its price‑to‑book sits at 1.35×, suggesting the stock is undervalued. The company delivered a robust 42.8% revenue growth year‑over‑year, with healthy operating margins (~23%) and a dividend yield of 3.2% backed by a modest payout ratio of 37%. However, the balance sheet is heavily leveraged, reflected by a debt‑to‑equity ratio of 222 and negative free cash flow, which raises concerns about long‑term financial flexibility. Technically, the share price sits near the support level of 3,766 and below the 20‑day SMA, while the MACD shows a bearish divergence, indicating short‑term downside pressure despite a broader bullish trend.
The low beta of 0.32 and a 30‑day volatility of 40% point to limited market‑wide price swings, while the stable volume profile suggests adequate liquidity. Given the attractive valuation, strong dividend, and growth momentum, the upside potential is estimated around 10.8%, but the high leverage and negative free cash flow temper confidence, making a cautious but optimistic stance appropriate.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price near support level with ~10% upside
  • Attractive dividend yield of 3.2%
  • Undervalued valuation relative to industry peers

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • High debt‑to‑equity ratio and negative free cash flow
  • Sustained revenue growth but leverage risk
  • Stable dividend and low market beta

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth trajectory
  • Low beta and modest volatility
  • Undervalued multiples and solid dividend sustainability

Key Metrics & Analysis

Financial Health

Revenue Growth42.80%
Profit Margin12.41%
P/E Ratio13.6
ROE10.38%
ROA2.76%
Debt/Equity222.81
P/B Ratio1.3
Op. Cash Flow¥32.1B
Free Cash Flow¥-48661250048
Industry P/E33.1

Technical Analysis

TrendBullish
RSI43.1
Support¥3,766.00
Resistance¥4,374.00
MA 20¥4,074.05
MA 50¥3,878.20
MA 200¥3,132.84
MACDBearish
VolumeStable
Fear & Greed Index80.77

Valuation

Target Price¥4,254.44
Upside/Downside10.76%
GradeUndervalued
TypeBlend
Dividend Yield3.20%

Risk Assessment

Beta0.32
Volatility40.85%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.